作者
Wei Dai,Yaqin Wang,Jia Liao,Xing Wei,Zhen Dai,Wei Xu,Yangjun Liu,Xin Shelley Wang,Cecilia Pompili,Hongfan Yu,Pu Yang,Yuqian Zhao,Bangrong Cao,Qifeng Wang,Wenhong Feng,Yuanqiang Zhang,Fang Liu,Yuanle Deng,Jin Zhou,Juan Li,Shao‐Hua Xie,Run Xiang,Xiang Wang,Bo Tian,Xiaozun Yang,Bin Hu,Xiaoqin Liu,Tianpeng Xie,Xiaojun Yang,Xiang Zhuang,Guibin Qiao,Qiang Li,Qiuling Shi
摘要
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We previously reported superior symptom control of electronic patient-reported outcome (ePRO)–based symptom management after lung cancer surgery for up to 1 month postdischarge. Here, we present the long-term results (1-12 months) of this multicenter, randomized trial, where patients were assigned 1:1 to receive postoperative ePRO-based symptom management or usual care daily postsurgery, twice weekly postdischarge until 1 month, and at 3, 6, 9, and 12 months postdischarge. Long-term patient-reported outcomes were assessed with MD Anderson Symptom Inventory-Lung Cancer module. Per-protocol analyses were performed with 55 patients in the ePRO group and 57 in the usual care group. At 12 months postdischarge, the ePRO group reported significantly fewer symptom threshold events (any of the five target symptom scored ≥4; median [IQR], 0 [0-0] v 0 [0-1]; P = .040) than the usual care group. From 1 to 12 months postdischarge, the ePRO group consistently reported significantly lower composite scores for physical interference (estimate, –0.86 [95% CI, –1.32 to –0.39]) and affective interference (estimate, –0.70 [95% CI, –1.14 to –0.26]). Early intensive ePRO-based symptom management after lung cancer surgery reduced symptom burden and improved functional status for up to 1 year postdischarge, supporting its integration into standard care.